News

Novartis plans to bring $1.1B research facility to San Diego
The company plans to develop 10 advanced facilities—seven of which will be entirely ... Novartis will bring a $1.1 billion ...
Business Wire1mon
Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors
SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage ... and preliminary clinical activity of ALTA3263 in adults with advanced unresectable or metastatic solid tumors with ...